400-0512-686

Apolipoprotein A1 detection kit (Immunoturbidimetry)

For in vitro quantitative determination of serum levels of apolipoprotein A1

【Clinical significance】

Apolipoprotein A1 and B is used as an important indicator of cardiovascular disease risk factors. ApoA1 is the major structural protein of HDL (about 65% HDL about the total protein), while ApoB is the major structural protein of LDL (LDL accounted for 98% of total protein), so ApoA1 ApoB can directly reflect LDL and HDL levels. Research data show that, ApoA1 down-regulation and ApoB up-regulation is risk factors for cardiovascular disease, which is also a good indicator for dyslipidemia.

【Test principle】

Mix serum (containing APOA1) and reagent (goat anti-human polyclonal antibody APOA1) to form insoluble immune complexes, which increases the turbidity of reaction solution.
Measure absorbance by spectrophotometer at a wavelength of 340nm.
The turbidity reflects the concentration of APOA1 in the sample, which can be read out by a working curve calibrated by standard serum.

【Storage conditions and validity】

Stable for one year when stored at 2~8 ℃ in the dark (freeze prohibited),
Stable at 2~8 ℃ for one month after initial use.

【Note】

1. The amount of reagent and sample might need to increase or decrease under the same proportion to meet the requirement of biochemical analytical instruments.
2. When the samples APOA1 concentration exceeds 220.0mg/dL, dilute with 0.9% saline for a maximum of 10 times and test again.
3. 0.05% Proclin-300 is contained as a preservative. NO SWALLOW and avoid contact with skin and mucous membranes. If you accidentally contact with skin or mucous membranes, rinse immediately with plenty of water and go to hospital for treatment.
4. Sheep-derived antibodies are included, which is a potential risk of infection. NO SWALLOW and avoid contact with skin and mucous membranes.℃℃℃ ℃




Top

Earlier
April 2014

Lumigenex receives CFDA approval for four POCT immunoassay kits to help physicians quickly and accurately diagnose heart diseases.

March 2014

Lumigenex receives CFDA approval for five immunoassay reagents adaptable to most chemical analyzers.

February 2014

Lumigenex received CFDA approval for time-resolved fluorescence immunochromatographic analyzer.

January 2014

Dr. He Aimin was named "National Thousand Talents Program"

December 2013

Lumigenex access to "high-tech enterprises in Jiangsu Province" title.

September 2013

Lumigenex passed The first Food and Drug Administration by the Suzhou Municipal Quality Management System Assessment.